BioNTech stock rises 15% within 6 months of Trump re-election announcement

BioNTech, a key player in mRNA technology, will benefit from accelerated FDA approvals under Trump, as its pipeline gains priority. Market optimism will drive stock appreciation despite potential long-term regulatory risks.

Implied probability (Yes)

62%